MedTrace Logo

FTIH of ECC5004 in Healthy and Diabetic Participants

NCT05654831 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2024-07-17

No results posted yet for this study

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of ECC5004 in healthy participants and in patients with Type 2 Diabetes Mellitus

Conditions

Interventions

DRUG

Placebo

Matching Placebo will be administered as oral tablet. Matching Placebo will be given orally during each dosing day.

DRUG

ECC5004

ECC5004 will be administered as oral tablet(s) during each dosing day.

Sponsors & Collaborators

  • Eccogene

    lead INDUSTRY

Principal Investigators

  • Eccogene · Eccogene Clinical Trials

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2023-11-01
Completion
2023-11-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05654831 on ClinicalTrials.gov